close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Otsuka Pharmaceutical Co., Ltd.

News headline image
Otsuka Presents New Phase 3b Results for SIMTRIYO® (centanafadine) Highlighting Consistent Improvements Across ADHD Symptoms, Anxiety, and Associated Features in Adults with ADHD and Comorbid Anxiety Disorders at Psych Congress 2026
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
Otsuka Unveils Unprecedented Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilizes Kidney Function Decline to Baseline Physiologic Rate, Fundamentally Altering Disease Progression in IgA Nephropathy (IgAN)
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients Aged 6 Years and Older
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
Otsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Prevented Progression to Kidney Failure and Improved Kidney Function in IgA Nephropathy (IgAN)
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
Otsuka Announces Positive Phase 3b Results for Centanafadine in Adults with ADHD and Comorbid Anxiety
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
Otsuka Completes Acquisition of Transcend Therapeutics to Advance Next-Generation Neuropsychiatric Treatments
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
Otsuka Presents Positive Interim Phase 3 VISIONARY eGFR Data Showing VOYXACT® (sibeprenlimab-szsi) Preserved Kidney Function Over 12 Months in IgA Nephropathy (IgAN)
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
Otsuka Presents New Phase 3 Post Hoc Analyses of Centanafadine Highlighting Improvement in Executive Function and Emotional Dysregulation in Adults with ADHD at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
Otsuka Showcases New Efficacy and Safety Data of VOYXACT® (sibeprenlimab-szsi) in Patients with IgA Nephropathy (IgAN) at the 2026 ISN World Congress of Nephrology Highlighting the Impact of APRIL Inhibition
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
Otsuka Unveils New Repinatrabit Open-Label Extension Data in Phenylketonuria (PKU) Signaling Efficacy in Adolescents at the 2026 American College of Medical Genetics and Genomics (ACMG) Meeting
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
Otsuka Announces FDA Acceptance and Priority Review of New Drug Application for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
Otsuka Pharmaceutical Submits New Drug Application to U.S. FDA for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
Otsuka Sibeprenlimab Phase 3 Data Show a Statistically Significant and Clinically Meaningful Proteinuria Reduction for the Treatment of Immunoglobulin A Nephropathy (IgAN)
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
PBS and WETA Caregiving Documentary by Executive Producer Bradley Cooper Now Available to Stream
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
Otsuka Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
New Report Shows Nearly Half of U.S. States Are on the Threshold of a Caregiving Emergency
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
Otsuka Files Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
JAMA Psychiatry Publishes Results of Otsuka and Lundbeck's Phase 3 Trial of Brexpiprazole in Combination with Sertraline in Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
New Report Reveals U.S. Family Caregivers Perform Equivalent of a Staggering $873.5 Billion Worth of Labor, Would Surpass Revenue of Top Global Companies
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
Otsuka Announces Positive Interim Results from the Phase 3 Trial of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy in Adults
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
Barbara Corcoran Announces Collaboration with Otsuka and Lundbeck to Raise Awareness of Agitation in Alzheimer’s Dementia
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
Otsuka and Lundbeck Present New REXULTI® (brexpiprazole) Post Hoc Efficacy Data Analyses for Agitation Associated with Dementia Due to Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2024
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
Otsuka and Lundbeck Present Results from Three Clinical Trials of Brexpiprazole in Combination with Sertraline for the Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
Otsuka to Terminate Development of AVP-786
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
Otsuka Announces Interim Data from Phase 2b/c Trial Indicating New Investigational Compound May Shorten Tuberculosis Treatment
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
Otsuka and Lundbeck Present New Data Analyses on the Efficacy of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer’s Disease
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
Otsuka Announces Phase 3 Topline Results of AVP-786 in the Treatment of Agitation Associated With Dementia Due to Alzheimer’s Disease
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
Otsuka Pharmaceutical Announces Positive Topline Results From Two Pivotal Phase 3 Trials of Centanafadine as a Treatment for Adolescents and Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
Otsuka and Lundbeck Published Study Results Showing Aripiprazole 2-Month, Ready-to-Use, Long-Acting Injectable is as Well-Tolerated, and Provides Similar Plasma Levels as Aripiprazole 1-Month for Treatment of Schizophrenia and Bipolar I Disorder
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
News headline image
Otsuka and Lundbeck Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.